S-ClassAbout S-Class
J
JAZZAI Stock Diagnostic Report
Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks
Jazz Pharmaceuticals has received approval from the FDA for the inclusion of the cancer treatment Ziihera in its therapy.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$263.43499755859375Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support240.63
Near-Term Resistance265.05
02
FUNDAMENTALS
Financial & Fundamental Analysis
The acquisition of FDA approval for the core oncology drug pipeline is expected to contribute to the enhancement of the company's long-term value through the visibility of related treatment sales in the future.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current stock price is located near the 20-day resistance level ($265.05) and is maintaining a stable, gentle upward trend above the support level ($240.63).
Support240.63
Resistance265.05
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Jazz Pharmaceuticals' cancer treatment Ziihera, developed in collaboration with BeOne Medicines and Zymeworks, has received FDA approval and is entering the commercialization stage.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-25)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.